Researchers have not yet chosen which protein they will fold when Blue Gene is finished a few years down the road, but Horn said that simpleproteins will be tested before then.
The theory behind targeted cancer drugs is simple: find the key gene mutations driving growth of tumors and then devise drugs that block those mutated proteins.